Vanguard Portfolio Management
LUCD icon

Vanguard Portfolio Management’s Lucid Diagnostics LUCD Stock Holding History

Vanguard Portfolio Management’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.09M Buy
1,022,262
+493,493
+93% +$532K ﹤0.01% 2936
2026
Q1 		$608K Buy
+528,769
New +$673K ﹤0.01% 2924

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Vanguard Portfolio Management's LUCD Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Lucid Diagnostics (LUCD) stake by 93% in Q2 2026, buying an estimated $532K and bringing the position to 1,022,262 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #2936.

Vanguard Portfolio Management first reported a position in LUCD in Q1 2026 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Vanguard Portfolio Management held 1,022,262 shares of Lucid Diagnostics worth $1.09M as of Q2 2026.
  • Vanguard Portfolio Management bought 493,493 Lucid Diagnostics shares in Q2 2026, an estimated $532K.
  • Lucid Diagnostics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2936 holding.
  • Vanguard Portfolio Management first reported a position in Lucid Diagnostics in Q1 2026 and has held it in 2 quarters since.
  • 114 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.